Develops Prime Editing medicines for patients with genetic diseases, including liver and lung conditions and blood disorders, and works with partners on edited T-cell programs for cancer and immune diseases.
10-K for FY2025, filed Mar 3, 2026We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentiallyโฆView โ
Our lead program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported byโฆView โ
Our organization is intentionally structured to support clinical development and regulatory engagement as we prepare for multiple parallelโฆView โ
Partners pay Prime under research collaboration and licensing agreements through upfront fees, cost reimbursements, option and milestone payments; Prime earns revenue over the expected work period under each agreement.
10-K for FY2025, filed Mar 3, 2026
$4.6M
10-K for FY2025, filed Mar 3, 2026
$4.6M โ
Research and licensing partners work with Prime through agreements; its collaboration with Bristol-Myers Squibb applies Prime Editing to ex vivo T-cell engineering. Prime expects revenue primarily from current and future collaboration agreements.
10-K for FY2025, filed Mar 3, 2026Our organization is intentionally structured to support clinical development and regulatory engagement as we prepare for multiple parallelโฆView โ
To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for theโฆView โ
The Company enters into collaboration and licensing agreements with partners under which it may exclusively license rights to researchโฆView โ
No. It lost $201.1M in FY2025.
10-K for FY2025, filed Mar 3, 2026
โ$208.4MView โ
10-K for FY2025, filed Mar 3, 2026
โ$201.1MView โ
8-K, filed Apr 16, 2026
On April 7, 2026, the Board of Directors (the โBoardโ) of Prime Medicine, Inc. (the โCompanyโ) appointed Svetlana Makhni as the ChiefโฆView โ
Narrower development focus
The older report described programs spanning blood, liver, eye and ear diseases and several delivery methods; the latest centers internal development on liver-directed in vivo editing, while continuing cystic fibrosis research and partnered ex vivo T-cell work.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 3, 2026To maximize the potential of our Prime Editing technology to provide one-time curative genetic therapies to the broadest set of diseasesโฆView โ
We believe our Prime Editing programs are well-positioned to leverage the clinical, regulatory, and manufacturing advancements made to dateโฆView โ
We have constructed our portfolio of 18 investigational therapeutic programs, including one partnered program, across our first twoโฆView โ
Competes with CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Caribou Biosciences, Beam, Verve Therapeutics, Tessera Therapeutics, Metagenomi Therapeutics, Scribe Therapeutics, Arbor Biotechnologies, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Sarepta Therapeutics, Wave Life Sciences, Moderna, Ultragenyx, Genetix Biotherapeutics, 4D Molecular Therapeutics, Vertex Pharmaceuticals, and Arrowhead Pharmaceuticals
10-K for FY2025, filed Mar 3, 2026The development of genetic medicines is highly competitive and rapidly evolving, with multiple companies pursuing therapeutic approachesโฆView โ
Loading...